Imiquimod 5% cream with prior curettage — Competitive Intelligence Brief

Imiquimod 5% cream with prior curettage (Imiquimod 5% cream with prior curettage) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TLR7 agonist / Immune response modifier. Area: Oncology / Dermatology.

phase 3 TLR7 agonist / Immune response modifier TLR7 (Toll-like receptor 7) Oncology / Dermatology Small molecule

Target snapshot

Imiquimod 5% cream with prior curettage (Imiquimod 5% cream with prior curettage) — Maastricht University Medical Center. Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to enhance local anti-tumor and anti-viral immunity.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Imiquimod 5% cream with prior curettage TARGET	Imiquimod 5% cream with prior curettage	Maastricht University Medical Center	phase 3	TLR7 agonist / Immune response modifier	TLR7 (Toll-like receptor 7)
Imiquimod 5% Cream	Imiquimod 5% Cream	Massachusetts General Hospital	marketed	TLR7 agonist / Immune response modifier	TLR7 (Toll-like receptor 7)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TLR7 agonist / Immune response modifier class)

1. Maastricht University Medical Center · 1 drug in this class
2. Massachusetts General Hospital · 1 drug in this class